Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Medicine and Dentistry

• Glomerular Filtration Rate 100%
• Chronic Kidney Disease 100%
• Creatinine 100%
• Albumin 100%
• Empagliflozin 100%
• Urinary System 100%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 40%
• Albuminuria 30%
• Cotransporter 30%
• Diabetes 20%
• Morbidity 10%
• Disease Exacerbation 10%
• Nephropathy 10%
• Intention-to-Treat Analysis 10%
• Placebo 10%
• Cardiovascular System 10%
• Oral 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Kidney Failure 100%
• Creatinine 100%
• Empagliflozin 100%
• Albumin 100%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 40%
• Albuminuria 30%
• Cotransporter 30%
• Placebo 10%
• Morbidity 10%
• Kidney Disease 10%
• Disease Exacerbation 10%